Scientific Publications - Arcellx

Our Technology

12.07.2020

Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory Multiple Myeloma. Data presented at the 62nd ASH Annual Virtual Meeting, December 5–8, 2020.

06.22.2020

Chimeric antigen receptors incorporating novel binding domains targeting CD123 direct potent antitumor activity of T cells: Correlation between affinity and activity (Abstract 3243). Presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.

05.29.2020

Selective targeting of HER2-overexpressing solid tumors with a next-generation CAR-T cell therapy (Abstract 3041). Presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting.

04.29.2020

Novel CAR-T Cell therapy that can be activated, silenced, and reprogrammed in vivo with soluble protein adapters in a dose dependent manner (Abstract 788). Presented at the American Society of Gene & Cell Therapy (ASGCT) 2020 Annual Meeting.

04.17.2019

Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells. Mol Ther. 2019 Jul 3; 27(7): 1262–1274. Published online 2019 Apr 17. doi: 10.1016/j.ymthe.2019.04.010. .